Compare AMCX & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCX | FHTX |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.6M | 323.4M |
| IPO Year | 2011 | 2020 |
| Metric | AMCX | FHTX |
|---|---|---|
| Price | $8.66 | $3.99 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $7.33 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 391.3K | 112.3K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.55 | 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,311,801,000.00 | $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $5.41 | $3.27 |
| 52 Week High | $10.28 | $6.95 |
| Indicator | AMCX | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.56 | 39.06 |
| Support Level | $7.62 | $3.65 |
| Resistance Level | $8.95 | $5.82 |
| Average True Range (ATR) | 0.42 | 0.26 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 64.70 | 31.25 |
AMC Networks owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.